Pharmaceutical

PLx Pharma (NASDAQ:PLXP) a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today certain financial and operational results for the three- and 12-month periods ended December 31, 2017. As quoted in the press release: “When considering the need to deliver …

PLx Pharma (NASDAQ:PLXP) a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today certain financial and operational results for the three- and 12-month periods ended December 31, 2017.

As quoted in the press release:

“When considering the need to deliver the highest-quality product to cardiovascular patients and the overall size of the Aspertec opportunity, it became clear that obtaining an alternate supply for this ingredient was in the long-term interest of the patient, the Aspertec brand and PLx. We must prioritize product quality and uninterrupted supply to patients who need and will be depending on Aspertec to maintain their cardiovascular health in the future,” said Natasha Giordano, President and Chief Executive Officer of PLx Pharma.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX21058.18-146.98
TSXV890.35-10.52
DOW34715.39-313.26
S&P 5004482.73-50.03
NASD14154.02-186.23
ASX7342.40+9.90

COMMODITIES

Commodities
Gold1840.85+2.00
Silver24.44+0.06
Copper4.51-0.07
Palladium2041.50+7.50
Platinum1035.50-0.49
Oil83.75-1.80
Heating Oil2.58-0.04
Natural Gas3.88+0.08

DOWNLOAD FREE REPORTS

×